Literature DB >> 1346113

CD4+ T cell-mediated killing of major histocompatibility complex class II-positive antigen-presenting cells (APC). III. CD4+ cytotoxic T cells induce apoptosis of APC.

D Grogg1, S Hahn, P Erb.   

Abstract

A subset of CD4+ T cells, belonging to the T helper type 1 (Th1) cells, kills antigen-presenting cells (APC) in an antigen-specific and major histocompatibility (MHC) class II-restricted way. Evidence is presented that CD4+ cytotoxic T lymphocytes (CTL) induce apoptosis or programmed cell death within susceptible APC as witnessed by quantitative DNA fragmentation. Apoptosis is more reliable to determine cell death than the 51Cr-release assay, because some cells demonstrate resistance to CD4-mediated lysis in the 51Cr-release assay. Apoptosis becomes manifest after 2 to 4 h of incubation preceding the disintegration of the target cells which is detectable between 12 and 24 h as measured by the 51Cr-release assay. Unstimulated B cells, which are not killed, but function as APC, do not undergo apoptosis, whereas lipopolysaccharide or anti-mu-activated B cell blasts show apoptosis and are efficiently lysed. Several CD4+ Th2-type cells tested, which did not demonstrate killing of APC as measured by the 51Cr-release assay, are unable to mediate programmed cell death of appropriate APC. Actinomycin D or cycloheximide, inhibitors of transcription and translation, respectively, fail to prevent apoptosis of APC excluding the involvement of newly synthesized soluble products as mediators of killing. Pretreatment of CD4+ CTL, but not of APC with 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, a specific inhibitor of the anion transport, efficiently prevents apoptosis of APC, although the secretion of interleukins is not affected. We propose, that upon contact of the CD4+ CTL with APC, molecules of yet undefined nature are activated and released in a polar fashion at the contact site and induce the endogenous pathway of programmed cell death.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346113     DOI: 10.1002/eji.1830220139

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.

Authors:  Sadamu Homma; Hideo Komita; Yukiko Sagawa; Tsuneya Ohno; Gotaro Toda
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

2.  Altered antigen-presenting capacity of human monocytes after phagocytosis of bacteria.

Authors:  J Pryjma; J Baran; M Ernst; M Woloszyn; H D Flad
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

3.  Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.

Authors:  M Hishii; J T Kurnick; T Ramirez-Montagut; F Pandolfi
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

4.  Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody.

Authors:  Y Dohi; S Sunada; M Aoki; A Moriguchi; M Okabayashi; M Miyata; H Matsuda
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

5.  Suppression of diabetes mellitus in the non-obese diabetic (NOD) mouse by an autoreactive (anti-I-Ag7) islet-derived CD4+ T-cell line.

Authors:  N Chosich; L C Harrison
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

Review 6.  Normal and abnormal consequences of apoptosis in the human heart: from postnatal morphogenesis to paroxysmal arrhythmias.

Authors:  T N James
Journal:  Trans Am Clin Climatol Assoc       Date:  1994

7.  Adoptive Transfer of Tracer-Alloreactive CD4+ T Cell Receptor Transgenic T Cells Alters the Endogenous Immune Response to an Allograft.

Authors:  M L Miller; J Chen; M D Daniels; M G McKeague; Y Wang; D Yin; V Vu; A S Chong; M-L Alegre
Journal:  Am J Transplant       Date:  2016-05-13       Impact factor: 8.086

8.  Picornavirus-specific CD4+ T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner.

Authors:  S Ozaki; T Okazaki; K Nakao
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

10.  Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death).

Authors:  M C Peitsch; B Polzar; H Stephan; T Crompton; H R MacDonald; H G Mannherz; J Tschopp
Journal:  EMBO J       Date:  1993-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.